Sign inJoin waitlistJoin the waitlist

DU

David Ungar

Pediatrics / Pediatric Hematology-Oncology

Credentials: ·

Research

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
The Lancet Oncology · 2021 · 394 citations
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
Blood · 2021 · 156 citations
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Clinical Cancer Research · 2019 · 87 citations

BK
Brad Kahl
5 papers
MS
Melhem Solh
5 papers
Paolo Caimi
4 papers
Brian Hess
3 papers
Juan Alderuccio
3 papers
LH
Leonard Heffner
3 papers
Weiyun Ai
3 papers
Barry Shulkin
2 papers
Brandt Groh
2 papers
Deanna Mitchell
2 papers
Eric Kodish
2 papers
Erin Reid
2 papers